JP2022537142A5 - - Google Patents
Info
- Publication number
- JP2022537142A5 JP2022537142A5 JP2021573449A JP2021573449A JP2022537142A5 JP 2022537142 A5 JP2022537142 A5 JP 2022537142A5 JP 2021573449 A JP2021573449 A JP 2021573449A JP 2021573449 A JP2021573449 A JP 2021573449A JP 2022537142 A5 JP2022537142 A5 JP 2022537142A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025112473A JP2025138816A (ja) | 2019-06-12 | 2025-07-02 | 骨形成タンパク質６に対するヒト抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962860597P | 2019-06-12 | 2019-06-12 | |
| US62/860,597 | 2019-06-12 | ||
| PCT/US2020/036771 WO2020251924A1 (en) | 2019-06-12 | 2020-06-09 | Human antibodies to bone morphogenetic protein 6 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025112473A Division JP2025138816A (ja) | 2019-06-12 | 2025-07-02 | 骨形成タンパク質６に対するヒト抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537142A JP2022537142A (ja) | 2022-08-24 |
| JP2022537142A5 true JP2022537142A5 (https=) | 2023-06-15 |
| JP7807238B2 JP7807238B2 (ja) | 2026-01-27 |
Family
ID=71944214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573449A Active JP7807238B2 (ja) | 2019-06-12 | 2020-06-09 | 骨形成タンパク質６に対するヒト抗体 |
| JP2025112473A Pending JP2025138816A (ja) | 2019-06-12 | 2025-07-02 | 骨形成タンパク質６に対するヒト抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025112473A Pending JP2025138816A (ja) | 2019-06-12 | 2025-07-02 | 骨形成タンパク質６に対するヒト抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12612452B2 (https=) |
| EP (1) | EP3983436A1 (https=) |
| JP (2) | JP7807238B2 (https=) |
| AU (1) | AU2020292246A1 (https=) |
| CA (1) | CA3141266A1 (https=) |
| MA (1) | MA56203A (https=) |
| WO (1) | WO2020251924A1 (https=) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| EP2436376B1 (en) | 2007-09-28 | 2014-07-09 | BIND Therapeutics, Inc. | Cancer cell targeting using nanoparticles |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US20140086919A1 (en) | 2012-09-24 | 2014-03-27 | Herbert Y. Lin | Methods and compositons for regulating iron homeostasis by modulation of bmp-6 |
| AU2016211890B2 (en) | 2008-11-13 | 2018-03-22 | The General Hospital Corporation | Methods and Compositions for Regulating Iron Homeostasis by Modulation of BMP-6 |
| AR093620A1 (es) | 2012-12-17 | 2015-06-10 | Lilly Co Eli | Anticuerpos bmp-6 |
| UY36449A (es) * | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| GB2550114A (en) | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
-
2020
- 2020-06-09 AU AU2020292246A patent/AU2020292246A1/en active Pending
- 2020-06-09 CA CA3141266A patent/CA3141266A1/en active Pending
- 2020-06-09 WO PCT/US2020/036771 patent/WO2020251924A1/en not_active Ceased
- 2020-06-09 EP EP20750812.8A patent/EP3983436A1/en active Pending
- 2020-06-09 JP JP2021573449A patent/JP7807238B2/ja active Active
- 2020-06-09 US US17/617,657 patent/US12612452B2/en active Active
- 2020-06-09 MA MA056203A patent/MA56203A/fr unknown
-
2025
- 2025-07-02 JP JP2025112473A patent/JP2025138816A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6998895B2 (ja) | Ｌａｇ－３抗体、その抗原結合フラグメント、およびそれらの医薬的用途 | |
| JP2025111463A5 (https=) | ||
| KR102366682B1 (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| CA2189015A1 (en) | Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases | |
| CN112969719A (zh) | 双功能融合蛋白及其医药用途 | |
| RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
| CA3139025A1 (en) | Tigit and pd-1/tigit-binding molecules | |
| EP3714901A1 (en) | Lag-3 antibody pharmaceutical composition and use thereof | |
| CN104662153A (zh) | 针对转运体的抗体及其用途 | |
| JP2015503909A5 (https=) | ||
| JP2024024114A5 (https=) | ||
| CN107660151A (zh) | 抗‑cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途 | |
| JP2020522280A5 (https=) | ||
| CN107921129B (zh) | 组合及其用途 | |
| JP2020522281A5 (https=) | ||
| JP2021510523A5 (https=) | ||
| JP2024518844A5 (https=) | ||
| WO2019076277A1 (zh) | 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 | |
| US20250059266A1 (en) | Antibodies for treating alpha-synucleinopathies | |
| CN120603852A (zh) | 一种fap/cd40结合分子的药物组合物及其医药用途 | |
| JP2025511135A5 (https=) | ||
| JP2024540435A5 (https=) | ||
| JP2021533806A5 (https=) | ||
| JP2024505195A5 (https=) | ||
| JP2022537142A5 (https=) |